Sign Up for our Newsletter

NIPT
PRENATAL TESTING

Noninvasive prenatal testing for greater accuracy

OVERVIEW

More women deserve the right to NIPT

OVERVIEW
205973 (132850) cfDNA_Landscape-01

Early answers

Noninvasive prenatal testing (NIPT) consists in analyzing cell-free DNA (cfDNA) circulating in the maternal blood in order to detect fetal chromosomal abnormalities. Testing can be performed as early as 10 weeks of pregnancy.

Molecule of DNA forming inside the test tube equipment.3d rendering,conceptual image.

Safe and accurate

From a simple blood test, NIPT enables safe and early access to reliable results and helps reduce the number of unnecessary invasive procedures.

Close-up Of A Person's Hand Stamping With Approved Stamp On Document At Desk

Global Endorsement

International scientific societies have recognized cell-free DNA testing as the most sensitive and specific screening test for the common fetal aneuploidies, and recommended that it is offered to all pregnant women.1,2

NONINVASIVE PRENATAL TESTING RESOURCES

Expert Insights & Resources

Expand your knowledge with articles, training resources, news & webcasts for professionals and advocates alike.

NONINVASIVE PRENATAL TESTING RESOURCES
TESTING MENU

What You Can Screen For

Common Trisomies

Trisomy 21 (Down syndrome)

Down syndrome, also called trisomy 21, is associated with the presence of an extra copy of chromosome 21. It is the most common chromosomal disorder in liveborn children and, although typically random, does occurs more commonly in the offspring of women as they get older.
Common Trisomies

Trisomy 18 (Edwards syndrome)

Edwards syndrome, also called trisomy 18, is a chromosomal disorder associated with the presence of an extra chromosome 18. It is the second most common autosomal trisomy among liveborn children.
Common Trisomies

Trisomy 13 (Patau syndrome)

Patau syndrome, also called trisomy 13, is a chromosomal disorder caused by the presence of an extra chromosome 13 in all or some of the cells.
SCREENING PLATFORMS

Vanadis® NIPT platform: Built for All

Unlike complex and expensive sequencing-based platforms, Vanadis NIPT enables cost-efficient and high-performance screening for fetal aneuploidies. Making cell-free DNA testing accessible to more laboratories and more women, Vanadis is built for all.

SCREENING PLATFORMS
easy

Easy

precise

Precise

cost

Cost-Effective

OUR MOST POPULAR TECHNOLOGY

Featured Products

Vanadis® NIPT system

Vanadis® NIPT system

Fully automated and cost-effective NIPT solution enabling targeted cfDNA analysis with no PCR, no sequencing.
LifeCycle™ software

LifeCycle™ software

LifeCycle™ software is the complete data management solution for prenatal screening laboratories

Other prenatal screening solutions

shutterstock_364954436

Pre-eclampsia Management

Learn more
Body shot of a pregnant lady with hands on belly

Serum Screening

Learn more
shutterstock_1689772501 1

Sign up for our newsletter

Stay up-to-date on the latest developments related to noninvasive prenatal testing.

GET IN TOUCH

Take the next step

GET IN TOUCH

Speak to a salesperson

Talk to one of our product experts about the right solutions for you

Learn More

View more resources

Explore our articles and resources section for the latest information

Learn More

Read the lastest news

Stay up-to-date and peruse our top headlines.

Learn More

References

  1. Practice Bulletin Number 226: Screening for fetal chromosomal abnormalities. Obstet Gynecol. 2020; 136(4)
  2. Benn P, Borrell A, Chiu R, et al. Position statement from the Chromosome Abnormality Screening Committee. Prenat Diagn. 2015;35(8):725-734.

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.